arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

XBiotech Inc.

XBIT
$2.27 0.00 (+0.22%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

XBiotech Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $69.2M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -4.7%
FCF / Share $-0.29
Trailing P/E
Price / Book 0.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-5.50M
↑ +49.4%
Operating Margin Operating profit as % of sales
-380.3%
↓ -360.6%
FCF / Share Free cash flow per share
$-0.29
↓ -31.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
22
Financial Health
12
Cash Quality
59

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters